Ankit Mahadevia
2021
In 2021, Ankit Mahadevia earned a total compensation of $4.9M as Chief Executive Officer at Spero Therapeutics, a 130% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $327,618 |
---|---|
Option Awards | $2,650,765 |
Salary | $590,417 |
Stock Awards | $1,300,000 |
Other | $6,245 |
Total | $4,875,045 |
Mahadevia received $2.7M in option awards, accounting for 54% of the total pay in 2021.
Mahadevia also received $327.6K in non-equity incentive plan, $590.4K in salary, $1.3M in stock awards and $6.2K in other compensation.
Rankings
In 2021, Ankit Mahadevia's compensation ranked 2,701st out of 12,415 executives tracked by ExecPay. In other words, Mahadevia earned more than 78.2% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 2,701 | 78th |
Manufacturing | 1,065 | 81st |
Chemicals And Allied Products | 417 | 82nd |
Drugs | 364 | 83rd |
Pharmaceutical Preparations | 240 | 85th |
Mahadevia's colleagues
We found three more compensation records of executives who worked with Ankit Mahadevia at Spero Therapeutics in 2021.
News
Spero Therapeutics CEO Ankit Mahadevia's 2022 pay slips 13% to $4.2M
September 1, 2023
Spero Therapeutics CEO Ankit Mahadevia's 2021 pay jumps 130% to $4.9M
August 5, 2022
Spero Therapeutics CEO Ankit Mahadevia's 2019 pay jumps 148% to $1.8M
September 30, 2020
Spero Therapeutics Chief Medical Officer David Melnick receives $1.6M in 2018
April 26, 2019